Resources
33 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 4/2/2020 (updated 3/28/2024)
Funding Stability (Sustainability) Webinar Recording and Resources from March 10, 2020.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Independence Ballroom Salons A -C on Friday, March 6, 2020, at 9:00 AM and 11:15 AM
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 10/19/2020 (updated 3/29/2024)
The Providers Clinical Support System (PCSS) Mentoring Program support is recommended for clinicians who are contemplating or have recently begun prescribing MOUD and would like additional support. PCSS offers three tiers of service at no cost to the recipient: (1) a discussion forum, (2) the ability to submit a clinical question through the PCSS website, and (3) one-on-one mentoring.
Posted 10/29/2020 (updated 4/3/2024)
Triumph over the opioid epidemic requires ALL traditional and non-traditional partners to come to the table. Join us to explore strategies for increasing the reach and sustainability of rural community coalitions by ensuring the right partners are at your table and can contribute to solving this crisis rather than be consumed by it.
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.
Posted 3/2/2021 (updated 4/5/2024)